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Aberrant iPSC-derived human astrocytes in
Alzheimer's disease
VC Jones1, R Atkinson-Dell2, A Verkhratsky2,3 and L Mohamet*,2
The pathological potential of human astroglia in Alzheimer's disease (AD) was analysed in vitro using induced pluripotent stem cell
(iPSC) technology. Here, we report development of a human iPSC-derived astrocyte model created from healthy individuals and
patients with either early-onset familial AD (FAD) or the late-onset sporadic form of AD (SAD). Our chemically defined and highly
efficient model provides 495% homogeneous populations of human astrocytes within 30 days of differentiation from cortical
neural progenitor cells (NPCs). All astrocytes expressed functional markers including glial fibrillary acidic protein (GFAP),
excitatory amino acid transporter-1 (EAAT1), S100B and glutamine synthetase (GS) comparable to that of adult astrocytes in vivo.
However, induced astrocytes derived from both SAD and FAD patients exhibit a pronounced pathological phenotype, with a
significantly less complex morphological appearance, overall atrophic profiles and abnormal localisation of key functional
astroglial markers. Furthermore, NPCs derived from identical patients did not show any differences, therefore, validating that
remodelled astroglia are not as a result of defective neural intermediates. This work not only presents a novel model to study the
mechanisms of human astrocytes in vitro, but also provides an ideal platform for further interrogation of early astroglial cell
autonomous events in AD and the possibility of identification of novel therapeutic targets for the treatment of AD.
Cell Death and Disease (2017) 8, e2696; doi:10.1038/cddis.2017.89; published online 23 March 2017
All diseases, including neurological disorders, can be broadly
defined as homeostatic failures within tissues, organs or
systems. Astroglia are highly heterogeneous neural cells
primarily responsible for homeostasis and neuroprotection
in the CNS. Astrocytes are fundamental for synaptogenesis
and synaptic maintenance; they control ion homeostasis in the
CNS interstitium and are indispensable for turnover of
major neurotransmitters, such as glutamate, GABA and
adenosine.1,2 In addition, astroglial cells are endowed with
an evolutionary conserved defensive programme known as
reactive gliosis, which develops in response to CNS lesions
and is manifested by a spectrum of disease-specific cellular
responses including hypertrophy and upregulation of inter-
mediate filaments.3,4 Astrocytopathy is a central element of
neurological disorders and, depending on the disease context,
astrocytes undergo complex changes, which vary from
astroglial atrophy with loss of function, to pathological
remodelling or reactivity and may develop alone or in
combination.5–8 In Alzheimer’s disease (AD) animal models,
atrophic astrocytes have been detected at the earliest stages
of the disease, with hypertrophic reactive astrocytes appear-
ing later in disease progression, in response to their proximity
to extracellular accumulations of β-amyloid (Aβ).9–12 Similarly,
signs of astroglial reactivity and atrophy were detected in AD
patients by positron emission tomography using 11C-deterium-
L-deprenyl.13 These observations led to a hypothesis of glial
paralysis being a fundamental factor in evolution of AD.14
The sporadic (late-onset) form of AD (SAD), which iswithout
significant non-Mendelian genetic bias, dominates human
pathology. Nevertheless, most of our knowledge of AD derives
from studies that utilise cell- and animal-based models of the
clinically rare, early-onset, dominantly inherited familial AD
(FAD). The cellular pathology of astroglia in the context of
human AD remains enigmatic, mainly because of severe
limitations of animal models, which, although reproducing
some pathological features of the disease, do not mimic its
progression in full. Neuronal loss and cognitive deficits, which
are the hallmarks of AD in humans, are limited in animal
models15 and there is an increasing body of evidence showing
that significant differences exist between rodent and human
astrocytes.16 Although induced pluripotent stem cell (iPSC)
technology can be used to investigate human astrocyte
development and function, only a limited number of studies
have described homogeneous generation of healthy
astrocytes.17–22 Previous work has shown that neurones
differentiated from SAD- and FAD-iPSCs resemble pathologi-
cally affected cells in vivo and express key disease
hallmarks;23–25 however, there is still a pressing need for
tools to provide robust, homogeneous astrocyte populations to
reveal astroglial contribution to neurodegenerative diseases.
Here we report the generation of enriched mature astroglia
from human iPSCs derived from patients with confirmed FAD
and SAD as well as from a healthy control. We found that,
although astrocytes derived from AD patients express the
same canonical markers of mature healthy astrocytes, their
morphological appearance and cellular phenotype is signifi-
cantly distorted. Notably, we did not observe any differences in
early neuronal commitment in early AD-derived neurones
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compared with healthy controls, indicating the cell autono-
mous pathological potential of astroglia and further confirming
that cellular pathology does not stem from defective neural
progenitors.
Results
Generation of neural cell lineages. Cortical NPCs were
propagated in monolayer culture and maintained as
described in ref. 24. Both FAD and SAD NPCs showed
indistinguishable culture morphology to healthy NPCs (N=5
per cell line; Figures 1a–c). Although a degree of variability in
cell proliferation and viability was observed between cells
from each individual, no significant differences in NPC growth
rates were identified (N= 4 per cell line, two-way Kruskal–
Wallis, Figures 1d and e). Phenotypic identification of NPCs
showed positive expression of the transcription factors SOX1
and PAX6, and the filamentous marker, nestin (Figures 1f–n).
However, no significant difference in NPC marker expression
was observed irrespective of genotype (quantified by the
proportion of immunoreactive nestin+ cells; N= 4 per cell line,
analysis of variance (ANOVA), F(2,9)=0.022, P=NS,
Figure 1o). Furthermore, under terminal neuronal differentia-
tion conditions for 35–40 days, all patient samples showed
positive expression of the neural marker β-III-tubulin
(Figures 1p–r). No significant difference was detected in the
efficiency of early neuronal induction (as measured by the
proportion of β-III-tubulin+ neurones) between any individual
(N=4 per cell line, ANOVA, F(2,9)=0.128, P=NS, Figure 1s).
Expression of the mature deep-layer cortical neuronal
marker, CTIP2 was observed throughout the cultures from
each patient, indicating maintenance of cortical identity
following 40 days in culture (Figures 1t–v). In a separate
study, we also show that cortical neurones derived from
identical FAD and SAD patients exhibit elevated pathological
Aβ-42 secretion and hyperphosphorylated tau species
compared with healthy individuals, therefore validating an
AD phenotype in these cells (data not shown). The results
presented herein reveal that both SAD and FAD NPCs retain
their characteristic morphology, expression of canonical
markers and are able to generate mature cortical neurones
with the same efficiency as healthy derived NPCs, Impor-
tantly, therefore, any changes in astroglia are not as a result
of defective neuronal intermediates.
To independently evaluate astroglial commitment, we
adapted a defined differentiation protocol18 to generate
purified astroglial cultures. We included additional culture
supplementation of EGF and insulin, which have been shown
to increase glial commitment, primary astrocyte proliferation
and sub-culturing in vitro.26,27 Astrocytes were generated
within 30 days following induction from cortical NPCs in each
cell line as confirmed by positive immunoreactivity to the
canonical marker, GFAP and mature astrocyte markers;
EAAT1, S100B and GS (Figures 2a–d). Quantification of
GFAP, EAAT1, S100B and GS immunoreactive cells revealed
near-pure expression in all astrocytes and no significant
differences were observed between astrocytes derived from
healthy control, FAD and SAD samples (N= 5 differentiations
per cell line (minimum 120 cells per group), ANOVA,
Supplementary Figures S1A–D). We also examined astrocyte
proliferation and viability (day 14 following induction) in both
AD and control cells. Despite some variability in growth rates
from each individual, no significant differences were observed
in overall astrocyte proliferation or viability (N= 3 per cell line,
two-way Kruskal–Wallis, Supplementary Figures S1E and F).
These results demonstrate that both PSEN1 mutant and
ApoE4+/+ NPCs are capable of generating astroglia in vitro
and retain expression of markers consistent with mature
astrocytes in vivo.
Altered cellular heterogeneity in FAD and SAD astro-
cytes. Our initial observations revealed considerable differ-
ences in astrocyte morphology in cells derived from AD-
NPCs compared with healthy controls. In healthy astrocytes,
GFAP staining intensities did not differ from cell to cell, but
overall morphology of individual cells across the population
varied significantly (Kruskal–Wallis; H(2)= 13.161, P=0.001,
N=3 differentiations). The majority of healthy astrocytes
(Figure 2g; 61.2%± 6.64; 93/145 cells) displayed long
(defined as 41× cell body width) branching fine processes
consistent with archetypal astrocyte phenotype (herein
referred to as ‘arborised’; Figure 2e). A significantly smaller
population showed a process-devoid, fibroblast-like pheno-
type (‘fibroblast-like’; 24.9%± 8.45; 33/145 cells; Dunn–
Bonferroni versus arborised cells, P=0.002; Figure 2f,
arrow). The remaining cells were thin, highly polarised, but
essentially process-devoid cells (‘polarised’; 13.9%± 3.59;
19/145 cells; Dunn–Bonferroni versus arborised cells,
P= 0.017; versus process-devoid cells, NS; Figure 2f, arrow-
head). In contrast, FAD and SAD astrocytes displayed
reduced morphological heterogeneity compared with healthy
cells. Specifically, FAD astrocytes comprise a significantly
greater proportion of fibroblast-like cells than any other
morphological type (Figure 3a, quantified in Figure 3e;
fibroblast-like cells, 97.0%± 1.38; 150/156 cells; Kruskal–
Wallis, H(2)=10.091, P=0.006; Dunn–Bonferroni versus
arborised cells, P= 0.047; versus polarised cells, P=0.008;
N=3 differentiations), despite their expression of mature
astrocyte markers. This proportion of fibroblast-like cells was
significantly greater than that seen with healthy astrocytes
(Figure 5a; H(2)=14.530, P=0.001; Dunn–Bonferroni,
P= 0.008). FAD astrocytes with an archetypal astrocyte-like
arborised morphology were rare and their relative proportion
was significantly reduced in comparison with healthy control
cells (1.94%± 0.84; 4/156 cells; Kruskal–Wallis,
H(2)=14.839, P=0.001; Dunn–Bonferroni, P=0.011). Simi-
larly, SAD astrocyte cultures comprise mainly process-devoid
fibroblast-like cells (Figure 4a; quantified in Figure 4e;
96.4%±2.64; 126/130 cells) with significantly fewer
arborised cells (2.72%±2.72; 3/130 cells; Kruskal–Wallis,
H(2)=11.129, P= 0.004; Dunn–Bonferroni versus fibroblast-
like, P= 0.013; N=3 differentiations) or polarised cells
(0.87%±0.87; 1/130 cells; Dunn–Bonferroni versus fibro-
blast-like, P=0.010). Again, there was a significant increase
in the proportion of fibroblast-like cells in SAD astrocytes
compared with healthy astrocytes (Figure 4a; Dunn–Bonfer-
roni, P= 0.004) concomitant with a reduction in the proportion
of arborised cells (Dunn–Bonferroni, P=0.002). Notably,
there was no significant difference in the relative proportions
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Figure 1 Directed differentiation of healthy and AD-neural progenitor cells into cortical neurones. (a–c) NPCs were seeded at 1 × 105 per well and propagated in monolayer
culture for 6/7 days. FAD and SAD cortical NPCs showed indistinguishable culture morphology with healthy (control) NPCs (N = 5 per cell line). (d and e) No significant
differences in NPC growth rates were identified (N= 4 per cell line, two-way Kruskal–Wallis P=NS). (f–n) IPS-derived NPCs from healthy (control), FAD and SAD patients were
assessed for canonical marker expression. Progenitor cells formed polarised rosettes expressing nestin (green; f–h), PAX6 (red; I–k) and SOX1 (green, l–n). (o) No significant
difference in nestin+ cells was observed between healthy and AD cell lines (N= 4 per cell line, ANOVA, F(2,9)= 0.022, P=NS). (p–r) Under terminal neuronal differentiation
conditions for 35–40 days, all patient samples showed positive expression of the neural marker β-III-tubulin (green). (s) No significant difference in the proportion of β-III-tubulin+
neurones between any individual (N= 4 per group, ANOVA, F(2,9)= 0.128, P=NS). (t–v) Expression of the mature deep-layer cortical neuronal marker, CTIP2 was observed
throughout cultures from each patient (green). Scale bars, 50 μm
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of each morphological cell type between the FAD and SAD
astrocyte groups. Moreover, no significant difference in
immunoreactive GFAP intensity was seen in any group
(Kruskal–Wallis, H(2)= 4.496, P=NS; Figure 5f), nor was any
loss of nuclear integrity or fragmentation of the GFAP
cytoskeleton observed. Taken together, these data demon-
strate that astrocytes derived from patients carrying a PSEN1
M146L mutation or both ApoE4 alleles display a significant
Figure 3 Induced astrocytes derived from PSEN1 M146L FAD patient fibroblasts express normal astrocyte markers but show reduced morphological heterogeneity
compared with healthy cells. Induced astrocytes were immunostained for GFAP (a), S100B (b), EAAT1 (c) and GS (d). Immunostaining is shown in green, DAPI counterstained
nuclei are shown in blue; 495% of observed cells were positive for all markers tested. The significant majority of FAD astrocytes display a fibroblast-like, process-devoid
appearance (summarised in e). **Po0.005, *Po0.05. Scale bars, 50 μm (inset, 20 μm)
Figure 2 Induced astrocytes derived from healthy patient fibroblasts express mature astrocyte markers and exhibit varied morphologies. Induced astrocytes were generated
in 30 days and confirmed by positive immunoreactivity to the functional markers: GFAP (a), S100B (b), EAAT1 (c) and GS (d). Immunostaining is shown in green, DAPI
counterstained nuclei are shown in blue. Heterogeneity of morphology within the population of induced astrocytes was evident, with cells falling into three broad categories when
stained for GFAP: arborised cells (e); polarised cells (f, arrowhead); or fibroblast-like, process-devoid cells (f, arrow); summarised in (g). **Po0.005, *Po0.05. Scale bars,
50 μm (inset, 20 μm)
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reduction in morphological heterogeneity when compared
with those derived from healthy individuals.
Induced astrocytes from FAD and SAD patients display
cellular atrophy. Three-dimensional reconstruction of the
entire GFAP cytoskeleton of astrocytes (Figure 6b top and
Supplementary Movie S1) permitted comparisons of surface
area and volume (Figures 5c and d). We found significant
differences between healthy, FAD and SAD astrocytes in both
their surface area and volume (surface area, Kruskal–Wallis;
H(2)=48.454, Po0.001; volume, Kruskal–Wallis; H(2)=48.085,
Po0.001). Specifically, FAD astrocytes displayed a significantly
reduced GFAP surface area and volume (2220.4±204.6 μm2
and 2574.4±307.5 μm3, respectively; N=3 per group) in
comparison with healthy astrocytes (9978.0±1048.0 μm2 and
20867.7±2102.2 μm3, respectively; N=3; Dunn–Bonferroni
pairwise comparisons: surface area, Po0.001; volume,
Po0.001). There was also a significant reduction in GFAP
surface area and volume in SAD astrocytes (1853.5±
171.0 μm2 and 2301.7±270.2 μm3, respectively; N=3 per
group) when compared with healthy astrocytes (Dunn–Bonfer-
roni pairwise comparisons: surface area, Po0.001; volume,
Po0.001). No significant difference was observed in either the
surface area or volume between FAD and SAD astrocytes
(Figures 4c and d), suggesting that astrocytic atrophy may be a
common feature in both forms of the disease.
To quantify astrocyte arborisation, we calculated the surface
area to volume ratio, SA:Vol (Figure 5e). A larger SA:Vol ratio
would indicate a cell with a relatively small cell body (low
volume) displaying many processes (large surface area),
whereas a small SA:Vol ratio would indicate a more rounded,
fibroblast-like cell (large volume) lacking processes (low
surface area). We found that the SA:Vol ratio was significantly
higher in healthy astrocytes (2.12± 0.07 μm− 1) compared
with either FAD or SAD cells (1.14± 0.05 μm− 1 and
1.19±0.05 μm− 1, respectively; Kruskal–Wallis; H(2)= 47.385,
Po0.001, Dunn–Bonferroni pairwise comparisons: healthy
versus FAD and SAD, both Po0.001; FAD versus SAD,
P=NS), indicating a greater degree of arborisation in healthy
over diseased cells. Again, these data reveal very little
difference between FAD and SAD astrocytes, indicating that
aberrant astrocyte morphology is a shared feature of both
forms of the disease.
Aberrant expression and localisation of S100B, EAAT1
and GS in AD astrocytes. In healthy astrocytes, S100B
expression was observed throughout the cytoplasm and, to a
lesser extent, in the nucleus, consistent with normal astro-
cytes in vivo (Figure 6a, top panel; Figure 6b, left;
Supplementary Movie S1). In contrast, both FAD and SAD
astrocytes displayed multiple large accumulations of S100B
localised to the nucleus, with very little staining in other
cellular compartments (Figure 6a, middle and bottom panels,
respectively). To confirm that S100B was confined within the
nuclei of diseased cells, we utilised z-sectioning confocal
microscopy and IsoSurface reconstruction to render 3D
models of the staining. Renders of GFAP and DAPI staining
were also made to permit comparisons. In both FAD and SAD
astrocytes, S100B expression was restricted to the nucleus
and confined to multiple, discrete foci following a similar
pattern to that of nucleoli (Figure 6b, centre and right;
Supplementary Movies S2 and S3, respectively). Fluores-
cence intensity analysis indicated that S100B levels were
significantly reduced in both FAD and SAD compared with
controls, but unchanged relative to each other (ANOVA,
F(2,16)=44.509, Po0.001; Hochberg’s GT2, healthy versus
FAD and SAD Po0.001, FAD versus SAD P=NS;
Figure 5g). In both healthy and FAD astrocytes, EAAT1
revealed a uniformed pattern of fluorescence extended
throughout the cell (Figures 2c and 3c, respectively). In
contrast, SAD astrocytes exhibited confined nuclear accu-
mulation of EAAT1 (Figure 4c). Quantification of fluorescence
Figure 4 Induced astrocytes derived from ApoE4+/+ SAD patient fibroblasts express classical astrocyte markers but show reduced morphological heterogeneity compared
with healthy cells. Induced astrocytes were immunostained for GFAP (a), S100B (b), EAAT1 (c) and GS (d). Immunostaining is shown in green, DAPI counterstained nuclei are
shown in blue. All observed cells were positive for all markers. A significant majority of SAD astrocytes displayed a fibroblast-like appearance, indicating limited heterogeneity of
morphology compared with healthy controls; summarised in (e). **Po0.005. Scale bars, 50 μm (inset, 20 μm)
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intensity revealed that EAAT1 levels were lower in both FAD
and SAD astrocytes compared with healthy cells, although
only FAD differed significantly (Kruskal–Wallis; H(2)=4.235,
P=0.001; Bonferroni, healthy versus FAD, Po0.001, versus
SAD, P=NS; Figure 5h). GS immunoreactivity in healthy
astrocytes revealed a uniform pattern of fine puncta through-
out the cytoplasm (Figure 2d, inset). In diseased cells,
however, this smooth pattern was lost and replaced with a
distinctly more clumped pattern of staining with much larger
puncta (FAD, Figure 3d, inset; SAD, Figure 4d, inset).
Fluorescence intensity analysis revealed GS levels were
lower in both FAD and SAD astrocytes compared with healthy
cells, although only FAD differed significantly (Kruskal–Wallis;
H(2)= 13.430, P=0.001; Bonferroni, healthy versus FAD,
P=0.001, versus SAD, P=NS; Figure 5i). Overall these data
reveal a drastic reorganisation of key proteins associated with
astrocyte function in both FAD and SAD.
Altered non-stimulated release of soluble inflammatory
mediators in AD Astrocytes. Non-stimulated astrocytes
were cultured under adherent culture conditions and astro-
cyte conditioned medium (ACM) simultaneously probed for
36 soluble mediators (Supplementary Table S1) using a
proteomic array (Supplementary Figures S2A–C). Astro-
cytes, irrespective of their genotype, constitutively secreted
only three cytokines: IL-8 (CXCL8), MCP-1 (CCL2) and
TIMP-2. However, SAD astrocytes additionally secreted
RANTES (CCL5) and MIP-1b. Quantification of expression
levels using densitometry showed that IL-8 and MCP-1
secretion was significantly decreased in both non-stimulated
ACM from FAD- and SAD-derived astrocytes compared with
control ACM (Dunn–Bonferroni; Po0.001 for both, N=3;
Supplementary Figure S2D). These results show that
human astrocytes secrete a distinct set of soluble
mediators under non-stimulated physiological conditions
Figure 5 Astrocytes derived from PSEN1M146L FAD and ApoE4+/+ SAD patients exhibit significant atrophy when compared with those from healthy patients as revealed by
visual binning according to overall morphology (a). Exemplar 3D IsoSurface renders constructed from serial confocal z-stacks display clear differences in cell size and overall
morphology (b). Scale bar, 10 μm. Quantification of cells using these renders by way of surface area (c), cell volume (d) and SA:Vol ratio (e) reveal significant differences in all
aspects of cellular morphology between healthy and diseased astrocytes. Quantification of mean fluorescence intensity per immunoreactive cell reveals no significant difference
in GFAP staining intensities between AD and control astrocytes (f) but S100B, EAAT1 and GS intensities are reduced in both FAD and SAD cells (g–i, respectively). ***Po0.001,
**Po0.005, *Po0.05
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in vitro and are partially compromised in both FAD and SAD
astrocytes.
Discussion
Since astrocytes are the main homeostatic units of the CNS,
their dysfunction may drive progression of neurologic dis-
orders, including AD. Astrocytes contribute to non-cell
autonomous mechanisms in various neurodegenerative dis-
orders that were previously thought of as classically neuronal
diseases.28,29 Here we report novel pathological astroglial
phenotypes in both FAD and SAD through exploitation of an
iPSC-based human model. We show evidence to support
critical astroglial contribution to AD namely: (i) mislocalisation
and abnormal expression of mature astrocyte markers, (ii)
compromised astrocyte heterogeneity and (iii) astroglial
atrophy. Singularly, we did not observe differences in early
maturation of AD-derived neurones compared to healthy
controls, showing that astroglial changes are cell autonomous
and do not derive from compromised neuronal intermediates
(Figure 7). Generation of functional astrocytes from healthy
iPSCs has previously been reported to be time-consuming
and result in 20–30% contamination of unwanted cell
types.18–20 In contrast, we demonstrate highly efficient
generation of enriched populations of mature cortical astro-
cytes (495%), irrespective of donor origin, within 30 days of
Figure 6 S100B localisation within astrocytes is dramatically altered in FAD and SAD Healthy astrocytes were immunostained for S100B and visualised using deconvolution
fluorescence microscopy (a) revealing S100B to be distributed throughout the cytoplasm (top panel). In contrast, in FAD and SAD cells, S100B appeared to be localised
exclusively at the nucleus (middle and bottom panels, respectively). Scale bar, 20 μm. IsoSurface renders of S100B (red) and of DAPI-stained nuclei (blue; with a clipping plane
set to permit visualisation of the inside of the nucleus) were constructed from serial confocal z-sections to further investigate the subcellular localisation of S100B (b; scale bars,
10 μm). GFAP staining (green) is shown for comparison for healthy cells to reveal the overall cell morphology. In healthy cells, as expected, S100B displayed a cytosolic
distribution, similar to that of GFAP. In both FAD and SAD astrocytes, S100B is localised exclusively to discrete foci within the nucleus. Nuclei images have been zoomed in × 2 for
clarity. Movies of these renders can be viewed in Supplementary Movies S1–S3
Aberrant human astrocytes in AD
VC Jones et al
7
Cell Death and Disease
induction. This is likely due to additional medium supplemen-
tation of EGF and insulin, both of which have been previously
shown to increase glial commitment and primary astrocyte
proliferation in vitro.26,27 Owing to a lack of astrocyte markers
that allow precise examination of subtypes that occur
throughout the CNS, we were not able to confirm their cortical
identity. However, it has been previously published that
maturation of neurones or glia from regionally specified
iPSC-derived NPCs maintain their identity.30 Critically, the
healthy iPSC-derived astrocytes described herein were
comparable in their morphology and marker expression to
those described in several previously published independent
studies; validating our differentiation protocol and model.18,19
Astrocytes exhibited 95–98% expression of GFAP, EAAT1,
GS and S100B irrespective of healthy or disease origin.
However, we observed significant redistribution and
decreased expression of S100B in FAD and SAD astrocytes
compared with healthy cultures. Although nuclear S100B
expression has previously been reported,18–20 its expression
has not been shown to be exclusively restricted to the nucleus/
nucleoli. Why S100B would localise to a nuclear sub-
compartment in pathologically remodelled astrocytes remains
to be established, but given that S100B is known to interact
with various cytoskeletal components, together with the
reduction in its expression levels, may represent a novel and
early mechanism underlying SAD- and FAD-induced astro-
cytic atrophy. Mislocalisation of astrocytic GS was also
observed in FAD and SAD astrocytes, however, altered
subcellular EAAT1 distribution was only observed in cultures
derived from SAD cells. Previous studies have shown altered
glutamatergic signalling in neuronal AD degeneration.31–33
Our results further reveal a previously unrecognised astroglial
cell autonomous pathological phenotype in AD, although a
significant reduction in the overall fluorescent intensities of
EAAT1 and GS was only seen in FAD-derived astrocytes. This
finding echoes our recent report of a significant decrease in
GS expression in the frontal cortex of 3xTg-AD murine
model,34 and may hint that astroglia-associated glutamate
turnover differs between the two forms of AD at an early stage.
We found that healthy induced astrocytes show significant
morphological heterogeneity, in accordance with morphologi-
cally distinct cortical astrocytic subpopulations in vivo,35
further validating the use of our cell-based model for the
interrogation of astroglial function. In contrast, FAD and SAD
astrocytes have reduced heterogeneity, are significantly
smaller than their healthy counterparts and exhibit an almost
complete absence of processes. This corroborates recent
studies in mousemodels of FAD showing reduced somata and
process volumes in astrocytes together with a reduction in the
number and complexity of astrocyte processes are an early
feature of the disease.10,11,36,37 Our results confirm that cell
autonomous astrocytic atrophy is a feature of early-onset FAD,
but also provide evidence that astrocytic aberrance is a likely
characteristic of SAD.
We also show evidence for an altered basal astrocyte
secretome profile in both FAD- and SAD- derived cells. Our
study of non-stimulated healthy astrocytes in culture express a
similar array of inflammatory mediators previously identified in
cultures from highly purified human fetal and adult
astrocytes.38,39 Furthermore, these mediators have been
previously shown to be direct targets of the transcription factor
NF-κB indicating that this pathway may be constitutively active
in human astrocytes under two-dimensional culture
conditions.38,39 We also observed significantly compromised
constitutive secretion of the pro-inflammatory mediators; IL-8
(CXCL8) and MCP-1 (CCL2) in FAD- and SAD-derived ACM,
both of which have been previously shown to be the most
abundantly expressed transcripts in adult healthy human
astrocytes in vitro.39 These early observations may indicate a
potential glial paralysis as such, which has been postulated to
be a fundamental factor in the evolution of AD.14 Although,
herein we describe the use of a single patient-derived cell line
for each criteria, it is reasonably common-place that articles in
this field are published whereby studies describe only a single
Figure 7 Comparison of healthy control, FAD and SAD patient-derived βIII-tubulin immunoreactive neurones and GFAP immunoreactive astrocytes. Early neuronal
appearance is indistinguishable across the groups, whereas AD astrocytes show markedly reduced heterogeneity of morphology and striking atrophy compared with healthy cells.
Scale bar, 50 μm
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patient-derived cell line due to the labour-intensive and cost-
prohibitive nature of induced pluripotent stem cell-derived
culture methods and differentiation protocols.17,40–45
However, it should be emphasised that cultured astrocytes
utilised in the present study represent a simplified model
relative to that of astrocytes in the CNS, whereby additional
interactions with other cell types and matrix components are
likely to influence the astrocytic phenotype. Yet, our highly
purified human astrocyte culture model presents a unique
system to delineate the autonomic responses of astrocytes to
defined stimuli/matrix/co-cultures in both healthy and AD-
affected cells.
Conclusions
Using a human in vitro iPSCmodel of familial and sporadic AD,
we demonstrate a significant and previously unknown cell
autonomous pathological phenotype of astroglia. Crucially,
neuronal intermediates derived from identical iPSCs obtained
from the same patients, did not show any pathological
phenotype when compared with healthy controls, further
corroborating recent ideas of the fundamental role of astroglia
in the development of neurodegenerative diseases. We may
further conjecture that early synaptic dysfunction, arising from
the inhibition of astrocyte–synapse interplay and disruption of
functional astroglial networks, is an early feature of AD
progression, supporting the idea of astrocytic atrophy as a
plausible mechanism for early cognitive impairment and
thus providing a potential novel therapeutic target for AD
intervention.
Materials and Methods
All reagents were purchased from ThermoFisher (Paisley, UK) unless stated
otherwise.
Derivation and maintenance of neuronal cell lineages. Human
iPSC-derived cortical neural progenitor cells (NPCs) were supplied by Axol
Bioscience (Cambridge, UK) and generated from patient dermal fibroblasts
exhibiting an M146L mutation in the presenellin-1 gene (PSEN1) from a 53-year-old
male donor clinically affected with type III early-onset FAD and from an 87-year-old
female clinically affected with late-onset SAD homozygous for the four allele of
apolipoprotein E (ApoE4+/+). The control samples were supplied by Axol
Bioscience and reprogrammed from human female umbilical cord blood cells
using the same method. NPCs were expanded following manufacturer guidelines
and expression of known NPC markers were confirmed before astroglial
differentiation.
For directed astroglial differentiation, NPCs were dissociated using accutase and
attached with a substrate of poly-L-ornithine (20 μg/ml; Sigma, Dorset, UK) and
mouse laminin (10 μg/ml) in chemically defined medium modified from Shaltouki
et al.18 comprising neurobasal medium containing B27 supplement (1 × ), non-
essential amino acids (1 × ), L-glutamine (2 mM), penicillin/streptomycin (50 U/ml),
8 ng/ml FGF2 (Peprotech, London, UK), 5 ng/ml CNTF and 10 mg/ml BMP2
(Peprotech) with additional supplementation of 10 ng/ml EGF and 5 μg/ml insulin.
NPCs were seeded at 3 × 104 cells/cm2 and maintained at 37 °C/5% CO2. The cells
were cultured until 80% confluence (approximately 5 days) and passaged twice, as
previously detailed. On the third passage, and all consecutive passages, the cells
were plated onto non-coated tissue culture plastic to remove unwanted neurones and
enrich for astroglia due to their superior adhesiveness. The cells were passaged at
least three times during astroglial commitment. Astrocytes were generated a
minimum of three times using independent differentiations from each patient sample.
For terminal neuronal differentiation, NPCs were seeded as above, but onto plates
coated with 20 μg/ml poly-L-ornithine and 10 μg/ml laminin. The cells were
maintained in a 1:1 mixture of N2:B27 media; where N2 medium comprised;
DMEM/F-12 with Glutamax, N2 supplement (1 × ), 1 mM L-glutamine, non-essential
amino acids (1 × ), 0.1 mM β-mercaptoethanol, 50 U/ml penicillin/streptomycin and
5 μg/ml insulin (Sigma); and B27 medium comprised Neurobasal, B27 supplement
(1 × ), 200 mM L-glutamine, 50 U/ml penicillin/streptomycin. Terminally differentiated
neurones were maintained for 30–40 days with medium changes every other day. The
cell counts and viability were performed using Trypan blue exclusion assay and
calculated using an automated cell counter. Population doubling times were
calculated when viable cells exhibited exponential growth. Neurones were generated
a minimum of three times using independent differentiations from each patient
sample.
Immunocytochemistry. The cells were fixed in 4% (w/v) paraformaldehyde
in phosphate-buffered saline (PBS) for 15 min and then treated with 0.1 M glycine in
PBS for a further 10 min to quench unreacted aldehydes. Fixed cells were
permeabilised by incubation in 0.1% (w/v) Triton X-100 in PBS for 5 min and
blocking of nonspecific binding was achieved by incubation with 1% (w/v) bovine
serum albumin (BSA) in PBS for 1 h. The cells were subsequently incubated for
30 min in 1% BSA/PBS containing rabbit polyclonal IgG antiserum for the glial
fibrillary acidic protein (GFAP; 1:100; Sigma), mouse monoclonal clone 1B2 IgG1κ
for S100 calcium-binding protein B (S100B; 1:100; Sigma), rabbit polyclonal IgG
antiserum for the excitatory amino acid transporter-1, (EAAT1; 1:200; Abcam,
Cambridge, UK), goat polyclonal antiserum for glutamine synthetase (GS; C-20;
1:100; Santa Cruz Biotechnology, Dallas, TX, USA), rabbit polyclonal IgG antiserum
paired box-6 (PAX6; 1:100; BioLegend, London, UK), recombinant monoclonal
rabbit IgG sex determining region-1 (SOX1; 1:100; Abcam), monoclonal mouse
IgG1 nestin (1:200; Abcam) or COUP-TF-Interacting Protein 2 (CTIP2; 1:300;
Abcam). Appropriate Alexa 488 or Alexa 546-conjugated fluorescent secondary
antibodies in 1% BSA/PBS with 0.1 μg/ml DAPI were applied (Sigma) for a further
30 min. Coverslips were mounted with ProLong Diamond antifade mountant, cured
overnight and sealed with nail varnish before imaging.
Fluorescence microscopy and image analysis. The fixed cells were
visualised using a Zeiss Cell Observer z-sectioning fluorescence imaging system
equipped Zeiss definite focus, HXP 120 V illumination and FITC, DsRed and DAPI
filter sets. Fluorescence images were acquired using × 20 PL Apo (0.8 NA), × 40
EC Plan-Neofluar (1.3 NA) oil and × 63 PL Apo (1.4 NA) oil objectives, AxioCam
MRm Rev.3 CCD camera and ZEN Pro software (Carl Zeiss, Cambridge, UK). The
images were collected as serial optical z-sections taken at 0.28 μm intervals, which
were subsequently deconvolved using a fast iterative algorithm with a maximum of
five iterations. The z-stacks were processed and analysed using FIJI ImageJ.46,47
All the images presented herein are maximum intensity projections of these
z-stacks unless otherwise indicated. Morphological analysis was carried out by
visually binning cells into one of three categories: fibroblast-like process-devoid
cells, process bearing arborised cells and polarised cells. A minimum of 130 cells
drawn from three separate batches of differentiated cells were analysed at × 20
magnification. Immunofluorescence intensity analysis was performed on a minimum
of five random fields for each of three separate batches of differentiated cells of view
at × 20 magnification using Fiji ImageJ. Z-stacks were flattened before the average
background fluorescence, calculated from three random regions of each field of
view, was subtracted. Raw integrated pixel densities of each image were calculated
and divided by the number of immunoreactive cells to determine an average
integrated pixel density per cell for each group.
To permit quantification of GFAP cytoskeleton volume and surface area, serial
optical z-sections were collected at 0.5 μm intervals using a Leica TCS SP5 AOBS
confocal microscope equipped with a × 63 HCX PL Apo (0.60–1.40 NA) oil objective,
405 nm and 488 nm laser lines and internal PMTs (Leica Microsystems (UK) Ltd,
Milton Keynes, UK). Throughout all experiments, the pinhole was set to one Airy unit.
The images were collected sequentially to minimise crosstalk using a bidirectional
scan at 1000 Hz and three frame averages. Z-stacks were carefully created so as to
include the entire thickness of each cell. Images were subsequently analysed using
Imaris 7.7.2 3D visualisation software (Bitplane AG, Zurich, Switzerland) using the
IsoSurface tool to create a smoothed 3D surface render of each cell by demarcating
the edges of the GFAP-positive cytoskeleton and removing voxels before calculating
GFAP surface area, volume and mean fluorescence intensity. A similar approach was
used to determine the subcellular localisation of S100B by creating 3D surface
renders of both S100B staining and DAPI-stained nuclei, before using a clipping plane
to slice the DAPI channel only, revealing S100B staining within the nucleus. In each
experimental group, a minimum of 21 randomly selected cells drawn from three
separate differentiations were analysed. To quantify neural progenitor-, neurone- and
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astroglial-marker expression, the cell counts were expressed as a percentage of total
cells in a field of view, where the total number of cells was identified using DAPI-
stained nuclei. The images were captured under standard epifluorescence on an
Olympus IX71 microscope (Olympus, Southend-on-Sea, UK) and analysed using
ImageJ. Five randomly chosen fields from three independent experiments were
assessed.
Antibody arrays. ACM was collected following 30 days in culture and stored at
− 80 °C analysis of inflammatory mediators using a human antibody array kit
(Abcam). ACM was collected following cell exposure for 48 h (normalised to cell
number) and samples analysed in parallel to enable comparisons in relative
expression levels between experiments. Each experiment represents pooled
medium from three independent differentiations. Before analysis, all the samples
were thawed on ice and centrifuged at 10 000 × g for 5 min at 4 °C. Cytokine/
chemokine secretion was measured according to the manufacturer's instructions.
Since, recombinant growth factors are present in ACM, a media-only control was
also run in parallel to normalise the data. Positive immunoreactivity was visualised
using chemiluminescence using a CCD camera (Bio-Rad, Hertfordshire, UK) and
positive/negative membrane controls permitted densitometric analysis using
Imagelab software (Bio-Rad).
Statistical analysis. All statistical analyses were carried out using IBM SPSS
22 (IBM Corp., Armonk, NY, USA). Data distributions were analysed by plotting
histograms and Quantile–Quantile plots followed by Shapiro–Wilks tests to determine
normality. For cell derivation and population analyses, each experiment was
performed a minimum of three times and all assays were repeated in triplicate. Mean
proportions of nestin+ NPCs and βIII-tubulin+ neurones were compared by one-way
ANOVA. Analyses of cell viability and proliferation rates, cell morphologies and
immunofluorescence intensity (with the exception of S100B) was carried out using
Kruskal–Wallis tests followed by pairwise comparisons by the Dunn–Bonferroni
method. S100B immunofluorescence intensity comparison was carried out by
ANVOA followed by a Hochberg’s GT2 post hoc. All the data are presented as
mean± standard error. An alpha level of 0.05 was considered significant throughout.
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